Article
Oncology
Sagun Parakh, Sze Ting Lee, Hui K. Gan, Andrew M. Scott
Summary: Monoclonal antibodies have the unique ability to target tumor-cell antigens, making them useful in delivering radioisotopes to tumor sites and in radioimmunotherapy. While the treatment of solid tumors remains challenging, various strategies are being investigated to improve the efficacy of radioimmunotherapy.
Review
Oncology
Ioannis Tsechelidis, Alexis Vrachimis
Summary: PSMA PET, the latest nuclear medicine development, is regarded as the most promising tool for the diagnosis and treatment of prostate malignancy. However, there is still debate and ongoing research regarding its utility and position in guidelines, requiring further studies and trials for clarification.
FRONTIERS IN ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Patricia M. R. Pereira, Jalen Norfleet, Jason S. Lewis, Freddy E. Escorcia
Summary: In this study, the utility of RTK-targeted immuno-PET was demonstrated in annotating RTK changes in protein expression and informing tumor response to targeted therapies. Targeted treatments affecting tumor growth and RTK protein levels were observed, highlighting the importance of annotating changes in RTK expression for targeted therapy.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Laura Gilardi, Lighea Simona Airo Farulla, Emre Demirci, Ilaria Clerici, Emanuela Omodeo Sale, Francesco Ceci
Summary: The tumor microenvironment (TME) is a complex system that promotes tumorigenesis, with cancer-associated fibroblasts (CAFs) playing a key role. Inhibitors targeting the fibroblast activation protein (FAP) have shown promise for molecular imaging and radio-ligand therapy, particularly in low FDG-avid tumors and unfavorable regions. However, more research is needed to determine the efficacy of this pan-tumoral approach.
Article
Oncology
Mengze Xu, Zhiyi Chen, Junxiao Zheng, Qi Zhao, Zhen Yuan
Summary: The use of artificial intelligence in biomedical imaging has shown its effectiveness in individualized cancer medicine. Optical imaging methods can provide detailed information of tumors with high contrast, low cost, and noninvasive property. However, there is a lack of systematic work on AI-aided optical imaging for cancer theranostics.
SEMINARS IN CANCER BIOLOGY
(2023)
Article
Chemistry, Medicinal
Nerella Sridhar Goud, Ahana Bhattacharya, Raman Kumar Joshi, Chandana Nagaraj, Rose Dawn Bharath, Pardeep Kumar
Summary: PET molecular imaging technique, with carbon-11 as a promising radiotracer, has become a valuable tool in medical diagnosis and biomedical research. Various carbon-11 PET radiotracers have been developed for imaging different diseases, targeting upregulated and emerging markers in oncology, cardiology, and neurology.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Travis Shaffer, Arutselvan Natarajan, Sanjiv S. Gambhir
Summary: This study developed novel PET probes for TIGIT, demonstrating high specificity and immunoreactivity for TIGIT. In mouse models, these probes showed potential applications in diagnosis and monitoring of therapeutic responses in tumors.
CLINICAL CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Emanuel Peplau, Francesco De Rose, Andreas Eichinger, Sybille Reder, Markus Mittelhaeuser, Giorgia Scafetta, Markus Schwaiger, Wolfgang A. Weber, Armando Bartolazzi, Calogero D'Alessandria, Arne Skerra
Summary: The study developed a PASylated humanized alpha hGal3 Fab for diagnostic imaging of thyroid cancer, achieving high sensitivity and specificity imaging of tumors through effective immunohistochemical staining and radiotracer labeling.
SCIENTIFIC REPORTS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Andrea Farolfi, Letizia Calderoni, Francesco Mattana, Riccardo Mei, Sivi Telo, Stefano Fanti, Paolo Castellucci
Summary: PSMA PET shows superior detection capabilities for prostate cancer in both primary and recurrent settings, with significant impact on clinical management. It may also play a crucial role in localization and treatment of PCa patients.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Review
Oncology
Yuchen Jin, Beibei Liu, Muhsin H. Younis, Gang Huang, Jianjun Liu, Weibo Cai, Weijun Wei
Summary: Molecular imaging utilizes radionuclides or artificially modified molecules to image specific disease targets, with newly developed probes enabling target-specific diagnosis and treatment of diseases. Advances in molecular imaging have led to the development of novel tracers based on aptamer, peptide, antibody, nanobody, antibody fragment, and nanoparticle platforms, supporting the management of diseases such as thyroid cancer.
Review
Pharmacology & Pharmacy
Panoraia Siafaka, Mehmet Evren Okur, Pelin Dilsiz Erim, Emre Sefik Caglar, Emre Ozgenc, Evren Gundogdu, Rabia Edibe Parlar Koprulu, Ioannis D. Karantas, Neslihan Ustundag Okur
Summary: Neurodegenerative disorders affect millions of people annually with no approved pharmacological approach for complete treatment. Recent studies suggest potential for reverting damaged adult brain cells and developing more efficient therapeutic strategies.
Review
Biochemistry & Molecular Biology
Valentin Duclos, Alex Iep, Lea Gomez, Lucas Goldfarb, Florent L. Besson
Summary: PET/CT molecular imaging has been widely used in clinical practice, driven by quantification and radiolabeled molecular probe vectorization. Despite efforts to standardize image analysis internationally, advanced metrics are still used in practice. The integration of PET imaging with radionuclide therapy has paved the way for highly sensitive radionuclide-based precision medicine research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Rodney J. Hicks, Peter J. Roselt, Kumarswamy G. Kallur, Richard W. Tothill, Linda Mileshkin
Summary: For over 40 years, F-18-FDG has been the dominant PET tracer in various fields such as neurology and cardiology, particularly in oncology. While other tracers are gradually gaining ground, none have been able to realistically compete with F-18-FDG for evaluating a broad spectrum of malignancies.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Review
Medicine, Research & Experimental
Paromita Sarbadhikary, Blassan P. George, Heidi Abrahamse
Summary: Photodynamic Therapy (PDT) has emerged as a promising alternative in cancer diagnosis and treatment, utilizing light-induced activation of photosensitizers to kill cancer cells. PDT offers advantages such as minimal invasiveness and spatio-temporal control, with proper planning of parameters being crucial for efficacy. The design of PS formulations for imaging-guided PDT has shown promising potential, with recent advances in activatable phototheranostic agents enhancing the specificity of treatment.
Article
Pharmacology & Pharmacy
Hanan Babeker, Jessica Pougoue Ketchemen, Arunkumar Annan Sudarsan, Samitha Andrahennadi, Anjong Florence Tikum, Anand Krishnan Nambisan, Humphrey Fonge, Maruti Uppalapati
Summary: This study developed a fully human antibody against MUC16 and evaluated its potential as an immuno-PET imaging probe for ovarian and pancreatic cancers. The antibody showed specific binding to MUC16-expressing cancer cells and stable uptake in tumor xenografts, indicating its effectiveness as a non-invasive imaging probe.
Article
Oncology
Lalitha K. Shankar, Erich Huang, Saskia Litiere, Otto S. Hoekstra, Larry Schwartz, Sandra Collette, Ronald Boellaard, Jan Bogaerts, Lesley Seymour, Elisabeth G. E. deVries
Summary: Currently, guidelines for PET with FDG-PET interpretation for therapy response in oncology involve visual evaluation of FDG-PET/CT scans. However, quantitative measurements of metabolic activity in tumors may be more useful. Guidelines based on such measurements have been proposed, but more analysis is needed for regular use.
CLINICAL CANCER RESEARCH
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Joyce van Sluis, Walter Noordzij, Elisabeth G. E. de Vries, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers, Ronald Boellaard
Summary: This study explores the influence of using manual segmentations versus an AI-based automated segmentation tool on calculating whole-body effective doses. The results show that using AI-based segmentations can save time and achieve higher similarity coefficients compared to manual segmentations. The whole-body effective doses show minimal differences for the six patients.
MOLECULAR IMAGING AND BIOLOGY
(2023)
Article
Oncology
S. F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N. J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E. G. E. de Vries, M. Piccart, N. I. Cherny
Summary: This article discusses the importance of quality of life (QoL) data and quality assurance measures in the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). Through field testing and revision, a checklist consisting of four items was developed to ensure the reliability and clinical relevance of QoL data. Implementation of this checklist will facilitate objective and transparent decision making in the ESMO-MCBS scoring process.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse, Lindsay Angus, Sandra Heskamp, Ingrid M. E. Desar, C. Willemien Menke-van der Houven van Oordt, Astrid A. M. van der Veldt, Anne I. J. Arens, Adrienne H. Brouwers, Bertha Eisses, Peter F. A. Mulders, Otto S. Hoekstra, Gerben J. C. Zwezerijnen, Winette T. A. van der Graaf, Erik H. J. G. Aarntzen, Wim J. G. Oyen, Carla M. L. van Herpen
Summary: Patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis can consider watchful waiting (WW), especially those who meet the watch and wait (W&W) criteria of < 2 International Metastatic RCC Database Consortium criteria and <=2 metastatic sites. This study aimed to assess the predictive value of [F-18]FDG PET/CT and [Zr-89]Zr-DFO-girentuximab PET/CT for the duration of WW in patients with mccRCC.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Ramsha Iqbal, Maqsood Yaqub, Huseyyin O. Bektas, Daniela E. Oprea-Lager, Elisabeth G. E. de Vries, Andor W. J. M. Glaudemans, Philippe Aftimos, Geraldine Gebhart, Andrew P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt
Summary: The purpose of this study was to investigate the use of [18F]-fluorodeoxyglucose ([18F]FDG) and [18F]-fluoro-17(3-estradiol ([18F]FES) PET/CT imaging in patients with metastatic ER-positive breast cancer undergoing treatment with rintodestrant. The study found that absence of ER expression on [18F]FES PET is a predictor for no response to rintodestrant. [18F]FES uptake during treatment and at time of progression is useful to monitor the effect of therapy and continued mode of action of SERDs.
CLINICAL CANCER RESEARCH
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Milou E. Noltes, Maximilian Bader, Madelon J. H. Metman, Jasper Vonk, Pieter J. Steinkamp, Jan Kukacka, Henriette E. Westerlaan, Rudi A. J. O. Dierckx, Bettien M. van Hemel, Adrienne H. Brouwers, Gooitzen M. van Dam, Dominik Juestel, Vasilis Ntziachristos, Schelto Kruijff
Summary: This study examines the potential of multispectral optoacoustic tomography (MSOT) for risk stratification of thyroid nodules. The findings show a correlation between vascular patterns and thyroid malignancy, and identify malignant features in MSOT images that are verified by histopathology. However, mean oxygen saturation does not provide significant differences between benign and malignant thyroid nodules. Recommendations are made to consider optoacoustic features and chromophore quantification together for malignancy risk assessment.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Joyce van Sluis, Ronald Boellaard, Rudi A. J. O. Dierckx, Evelien L. M. van Esch, Demi A. Croes, Laura Kist de Ruijter, Pim P. van de Donk, Elisabeth G. E. de Vries, Walter Noordzij, Adrienne H. Brouwers
Summary: ImmunoPET imaging is a non-invasive method to characterize tumor lesions and evaluate treatment response. The use of SiPM-based PET/CT systems can improve the sensitivity of Zr-89 immunoPET imaging. The scan duration using the Vision can be reduced up to 50% while maintaining image quality using the EARL1 compliant reconstruction protocol.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, Ignace H. J. T. de Hingh, Frank J. P. Hoebers, Agnes Jager, Gabe S. Sonke, Elisabeth G. E. de Vries, Carin A. Uyl-de Groot, Sabine Siesling
Summary: This study evaluated the changes in survival of patients with de novo metastatic solid cancers over the past 30 years. The proportion of M1 disease and net survival rates varied among different cancer types. Better preventive measures and early detection are needed to reduce the incidence of metastatic disease.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Elisabeth G. E. de Vries, Josef Rueschoff, Martijn Lolkema, Josep Tabernero, Luca Gianni, Emile Voest, Derk Jan A. de Groot, Daniel Castellano, Gilles Erb, Julia Naab, Margarita Donica, Regula Deurloo, Michiel S. van Der Heijden, Giuseppe Viale
Summary: This study aimed to investigate tumor HER2 expression and its effects on T-DM1 treatment in patients with HER2-positive urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. The results showed that some HER2-positive bladder cancer and pancreatic cancer patients responded well to T-DM1, and it also provided insight into the prevalence of HER2 positivity and expression patterns in these three non-breast tumor types.
Article
Oncology
Olivier J. van Not, Thijs T. Wind, Rawa K. Ismail, Arkajyoti Bhattacharya, Mathilde Jalving, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. Haanen, Ellen Kapiteijn, Manja Bloem, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Willeke A. M. Blokx, Karijn P. M. Suijkerbuijk, Rudolf S. N. Fehrmann, Geke A. P. Hospers
Summary: This study aimed to identify prognostic factors in advanced melanoma patients with brain metastases treated with immune checkpoint inhibitors. The analysis found that the serum lactate dehydrogenase (LDH) level was the strongest clinical parameter associated with survival.
Review
Oncology
Mostafa Roya, Samaneh Mostafapour, Philipp Mohr, Laura Providencia, Zekai Li, Johannes H. van Snick, Adrienne H. Brouwers, Walter Noordzij, Antoon T. M. Willemsen, Rudi A. J. O. Dierckx, Adriaan A. Lammertsma, Andor W. J. M. Glaudemans, Charalampos Tsoumpas, Riemer H. J. A. Slart, Joyce van Sluis
Summary: Recently, a new type of PET scanner with long axial field-of-view (LAFOV) has been introduced in clinical practice. Compared to conventional PET scanners, LAFOV scanners have a larger coverage and higher sensitivity, providing new opportunities for clinical applications, such as reducing scan time, decreasing the amount of radiotracer used, and using dynamic or parametric imaging. Emerging technologies like artificial intelligence and imaging with multiple radiotracers can further enhance the clinical application of LAFOV PET.
Article
Surgery
M. E. Noltes, L. Rotstein, A. Eskander, W. P. Kluijfhout, P. Bongers, A. H. Brouwers, S. Kruijff, U. Metser, J. D. Pasternak, P. Veit-Haibach
Summary: This study compared the diagnostic value of standard-of-care localization techniques to FCH-PET/MRI in primary hyperparathyroidism. The results showed that FCH-PET/MRI is a highly accurate imaging modality for localization of parathyroid adenomas and is superior to other techniques.
LANGENBECKS ARCHIVES OF SURGERY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Milou E. Noltes, Schelto Kruijff, Auke P. A. Appelman, Liesbeth Jansen, Wouter T. Zandee, Thera P. Links, Bettien M. van Hemel, Hugo M. Schouw, Rudi A. J. O. Dierckx, Anne Brecht Francken, Wendy Kelder, Anouk van der Hoorn, Adrienne H. Brouwers
Summary: In patients with pHPT and negative first-line imaging, [11C]choline PET/CT is superior to [11C]methionine PET/CT and 4D-CT in localizing parathyroid adenomas, allowing correct localization in 85% of adenomas. Further studies are needed to determine cost-benefit and efficacy of these scans, including the timing of these scans as first- or second-line imaging techniques.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)